Literature DB >> 28427842

Predominance of international clone 2 OXA-23-producing-Acinetobacter baumannii clinical isolates in Greece, 2015: results of a nationwide study.

Spyros Pournaras1, Konstantina Dafopoulou2, Mariateresa Del Franco3, Olympia Zarkotou4, Evangelia Dimitroulia5, Efi Protonotariou6, Aggeliki Poulou7, Raffaele Zarrilli3, Athanasios Tsakris5.   

Abstract

In a previous nationwide study in Greece, OXA-58 was the sole carbapenemase present among carbapenem-resistant Acinetobacter baumannii (CRAB) isolated between 2000 and 2009. In this study, the antibiotic resistances, carbapenemase gene content and clonal relatedness of 194 single-patient CRAB clinical isolates collected randomly during 2015 from 11 tertiary hospitals located throughout Greece were investigated. Antimicrobial susceptibility was determined using commercial and dilution methods. PCR assays for carbapenemase genes were performed. Clonality was tested by a scheme based on two multiplex PCRs and single-locus blaOXA-51-like sequence-based typing. Furthermore, Pasteur's multilocus sequence typing (MLST) scheme and pulsed-field gel electrophoresis (PFGE) were applied to 31 selected representative isolates. The most active antibiotics were trimethoprim/sulfamethoxazole (SXT) (34.6% of isolates susceptible), minocycline (71.6%), colistin (72.7%) and tigecycline (MIC50/90 values, 1/2 mg/L). The blaOXA-23-like gene was identified in 188 isolates (96.9%), blaOXA-23-like together with blaOXA-58-like in 3 isolates (1.5%), blaOXA-58-like in 2 isolates (1.0%) and blaOXA-40-like in 1 isolate (0.5%). ISAba1 was found upstream of the blaOXA-23-like gene in all isolates. International clone (IC) 2 comprised 157 isolates (80.9%), IC1 comprised 36 isolates (18.6%) and ST78 comprised 1 isolate (0.5%). All IC2 and IC1 isolates tested by MLST were ST2 and ST1, respectively. Seven PFGE types were detected. IC2 isolates were resistant to more antibiotics than IC1, except for SXT. This nationwide study showed that CRAB isolates in Greek hospitals currently produce almost uniformly the OXA-23 carbapenemase and belong mainly to IC2 and, to a lesser extent, IC1. Of particular concern, colistin susceptibility is recently severely reduced.
Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Clonal complex; Molecular epidemiology; Multilocus sequence typing; Oxacillinase; Single-locus (blaOXA-51-like) sequence-based typing

Mesh:

Substances:

Year:  2017        PMID: 28427842     DOI: 10.1016/j.ijantimicag.2017.01.028

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  15 in total

1.  Intercellular Transfer of Chromosomal Antimicrobial Resistance Genes between Acinetobacter baumannii Strains Mediated by Prophages.

Authors:  Jun-Ichi Wachino; Wanchun Jin; Kouji Kimura; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Polyclonal predominance of concurrently producing OXA-23 and OXA-58 carbapenem-resistant Acinetobacter baumannii strains in a pediatric intensive care unit.

Authors:  Theodoros Karampatakis; Katerina Tsergouli; Lida Politi; Georgia Diamantopoulou; Elias Iosifidis; Charalampos Antachopoulos; Aggeliki Karyoti; Maria Sdougka; Athanassios Tsakris; Emmanuel Roilides
Journal:  Mol Biol Rep       Date:  2019-04-12       Impact factor: 2.316

3.  The first nationwide multicenter study of Acinetobacter baumannii recovered in Serbia: emergence of OXA-72, OXA-23 and NDM-1-producing isolates.

Authors:  Bojana Lukovic; Ina Gajic; Ivica Dimkic; Dusan Kekic; Sanja Zornic; Tatjana Pozder; Svetlana Radisavljevic; Nataša Opavski; Milan Kojic; Lazar Ranin
Journal:  Antimicrob Resist Infect Control       Date:  2020-07-06       Impact factor: 4.887

4.  Investigation of multidrug-resistant ST2 Acinetobacter baumannii isolated from Saint George hospital in Lebanon.

Authors:  Tania Nawfal Dagher; Charbel Al-Bayssari; Selma Chabou; Nadine Antar; Seydina M Diene; Eid Azar; Jean-Marc Rolain
Journal:  BMC Microbiol       Date:  2019-02-02       Impact factor: 3.605

5.  Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii.

Authors:  Mohammad Hamidian; Steven J Nigro
Journal:  Microb Genom       Date:  2019-10

6.  Abundance of Colistin-Resistant, OXA-23- and ArmA-Producing Acinetobacter baumannii Belonging to International Clone 2 in Greece.

Authors:  Mattia Palmieri; Marco Maria D'Andrea; Andreu Coello Pelegrin; Nadine Perrot; Caroline Mirande; Bernadette Blanc; Nicholas Legakis; Herman Goossens; Gian Maria Rossolini; Alex van Belkum
Journal:  Front Microbiol       Date:  2020-04-15       Impact factor: 5.640

7.  Subtypes, resistance and virulence platforms in extended-drug resistant Acinetobacter baumannii Romanian isolates.

Authors:  Irina Gheorghe; Ilda Czobor Barbu; Marius Surleac; Ionela Sârbu; Laura Ioana Popa; Simona Paraschiv; Yu Feng; Veronica Lazăr; Mariana Carmen Chifiriuc; Dan Oţelea; Zong Zhiyong
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

8.  The role of the type VI secretion system vgrG gene in the virulence and antimicrobial resistance of Acinetobacter baumannii ATCC 19606.

Authors:  Jianfeng Wang; Zhihui Zhou; Fang He; Zhi Ruan; Yan Jiang; Xiaoting Hua; Yunsong Yu
Journal:  PLoS One       Date:  2018-02-02       Impact factor: 3.240

9.  Dual infections of two carbapenemase-producing Acinetobacter baumannii clinical strains isolated from the same blood culture sample of a patient in Iran.

Authors:  Linda Hadjadj; Saeed Shoja; Seydina M Diene; Jean-Marc Rolain
Journal:  Antimicrob Resist Infect Control       Date:  2018-03-10       Impact factor: 4.887

10.  High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial.

Authors:  J Nowak; E Zander; D Stefanik; P G Higgins; I Roca; J Vila; M J McConnell; J M Cisneros; H Seifert
Journal:  J Antimicrob Chemother       Date:  2017-12-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.